CYDY News and Press, CytoDyn Inc From 10/11/19

VANCOUVER, Washington, Oct. 11, 2019 (GLOBE NEWSWIRE) --   CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indicatio...

Phoenix, Arizona--(Newsfile Corp. - October 10, 2019) - The Stock Day Podcast welcomed CytoDyn Inc. (CYDY) ("the Company"), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR...

CytoDyn ( OTCQB:CYDY ) announces FDA clearance to initiate enrollment in its Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

VANCOUVER, Washington, Oct. 01, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...

VANCOUVER, Washington, Sept. 27, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications an...

VANCOUVER, Washington, Sept. 25, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) announces that Nader Pourhassan, Ph.D., President and Chief Executive Officer, will host an investment community conference call to provide an update on the Company. A live audio webcast may also b...

Every week, Seeking Alpha PRO+ Small and Micro provides subscribers with an exclusive roundup of must-read small- and microcap coverage on many underfollowed stocks. This week, we are making the newsletter available to all readers. To learn more about PRO+, please click here . Technol...

CytoDyn's 13 Shots on Goal De-risk's Investment 13 disease indications in the pipeline First approval possible in 2020 & low risk of drug failure Newest player in NASH Robust licensing and partnering potential Large revenue likely in 2020 CytoDyn Inc. ( CYDY ), the develo...

CytoDyn Inc. ( CYDY ) held its annual meeting of shareholders on September 12 th , where the typical counting of votes for the board and customary announcements were made. However, the bulk of the meeting was devoted to CEO Dr. Nader Pourhassan’s presentation on the state of the company...

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, video presentations, and news updates from the company’s presenting at last month’s NEXT SUPER STOCK Live! inves...